Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

被引:101
作者
Machado, Marcio
Iskedjian, Michael
Ruiz, Ines
Einarson, Thomas R.
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
[2] Pharmideas Res & Consulting Inc, Oakville, ON, Canada
[3] Univ Chile, Santiago, Chile
关键词
antidepressants; dropout rates; head-to-head trials; major depressive disorder; meta-analysis; remission rates;
D O I
10.1185/030079906X132415
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To summarize remission rates and dropouts due to adverse drug reactions (ADRs) or lack of efficacy (LoE) of serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin-reuptake inhibitors (SSRIs), and tricyclic antidepressants (TCAs) in treating major depressive disorder. Methods: We searched MEDLINE, EMBASE, IPA, and the Cochrane International Library from 1980-2005. Meta-analysis summarized outcomes from head-to-head randomized clinical trials comparing ! 2 drugs from three antidepressants classes (SNRIs, and/or SSRIs, and/or TCAs) followed by ! 6 weeks of treatment. Remission was a final Hamilton Depression Rating Scale (HAMD) score <= 7 or Montgomery-Asberg Depression Rating Scale (MADRS) <= 12. Intent-to-treat data were combined across study arms using random effects models, producing point estimates with 95% confidence intervals. Results: We obtained data from 30 arms of 15 head-to-head trials with 2458 patients. SNRIs had the highest ITT remission rate (49.0%), then TCAs (44.11%), and SSRIs (37.7%) (p > 0.05 for SNRIs versus TCAs; p < 0.001 for TCAs versus SSRIs and SNRIs versus SSRIs). When categorized as inpatients (n = 582) and outpatients (n = 1613), SNRIs had the highest remission rates (52.0% for 144 inpatients and 49.3% for 559 outpatients). SNRIs had lowest overall dropouts (26.1%), followed by SSRIs (28.4%), and TCAs (35.7%). Dropouts due to ADRs and LoE were 10.3% and 6.2% for SNRIs, 8.3% and 7.2% for SSRIs, and 19.8% and 9.9% for TCAs, respectively (p > 0.05 for ADR dropouts only). One limitation was the inclusion of only venlafaxine-XR; results may not be the same for immediate release forms. In addition, few studies reported remission rates. Conclusions: SNRIs had the highest efficacy remission rates (statistically significant for inpatients and outpatients), and the lowest overall dropout rates, suggesting clinical superiority in treating major depression.
引用
收藏
页码:1825 / 1837
页数:13
相关论文
共 73 条
[1]   Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram [J].
Allard, P ;
Gram, L ;
Timdahl, K ;
Behnke, K ;
Hanson, M ;
Sogaard, J .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (12) :1123-1130
[2]  
AMERONGEN APF, 2002, J AFFECT DISORDERS, V72, P21
[3]  
AMORE M, 1989, CURR THER RES CLIN E, V46, P815
[4]  
Andersen B, 1990, J AFFECT DISORDERS, V18, P289
[5]  
[Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
[6]   CONTROLLED COMPARISON OF 2 DOSES OF MILNACIPRAN (F-2207) AND AMITRIPTYLINE IN MAJOR DEPRESSIVE INPATIENTS [J].
ANSSEAU, M ;
VONFRENCKELL, R ;
MERTENS, C ;
DEWILDE, J ;
BOTTE, L ;
DEVOITILLE, JM ;
EVRARD, JL ;
DENAYER, A ;
DARIMONT, P ;
DEJAIFFE, G ;
MIREL, J ;
MEURICE, E ;
PARENT, M ;
COUZINIER, JP ;
DEMAREZ, JP ;
SERRE, C .
PSYCHOPHARMACOLOGY, 1989, 98 (02) :163-168
[7]   CONTROLLED COMPARISON OF MILNACIPRAN AND FLUOXETINE IN MAJOR DEPRESSION [J].
ANSSEAU, M ;
PAPART, P ;
TROISFONTAINES, B ;
BARTHOLOME, F ;
BATAILLE, M ;
CHARLES, G ;
SCHITTECATTE, M ;
DARIMONT, P ;
DEVOITILLE, JM ;
DEWILDE, J ;
DUFRASNE, M ;
GILSON, H ;
EVRARD, JL ;
DENAYER, A ;
KREMER, P ;
MERTENS, C ;
SERRE, C .
PSYCHOPHARMACOLOGY, 1994, 114 (01) :131-137
[8]   A 12-WEEK DOUBLE-BLIND MULTICENTER STUDY OF PAROXETINE AND IMIPRAMINE IN HOSPITALIZED DEPRESSED-PATIENTS [J].
ARMINEN, SL ;
IKONEN, U ;
PULKKINEN, P ;
LEINONEN, E ;
MAHLANEN, A ;
KOPONEN, H ;
KOURULA, K ;
RYYPPO, J ;
KORPELA, V ;
LEHTONEN, ML ;
VARTIAINEN, H ;
LEHTINEN, V ;
TAMMINEN, T ;
MANNICHE, PM .
ACTA PSYCHIATRICA SCANDINAVICA, 1994, 89 (06) :382-389
[9]   Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders [J].
Baca, E ;
Garcia-Garcia, M ;
Porras-Chavarino, A .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2004, 28 (01) :57-65
[10]   Sertraline is more effective than imipramine in the treatment of non-melancholic depression:: Results from a multicentre, randomized study [J].
Baca, E ;
de Chávez, MG ;
García-Toro, M ;
Pérez-Arnau, F ;
Porras-Chavarino, A .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (03) :493-500